A cancer therapy that targets aging cells could finally crack solid tumors
CAR T-cell therapy transformed blood cancer treatment. But for solid tumors — the most common cancers — it has largely failed.
CAR T-cell therapy works by engineering a patient’s own immune cells to recognize and kill specific targets. In blood cancers like leukemia, the results have sometimes been remarkable. In solid tumors — breast, lung, colon cancer — the approach has repeatedly struggled. Tumors create a hostile microenvironment that exhausts and excludes T-cells before they can do meaningful damage. The engineered cells arrive, encounter resistance, and fail.
A new study describes a strategy that partially sidesteps this problem by targeting uPAR, a protein expressed on the surface of senescent cells. Senescent cells are ones that have stopped dividing but refuse to die — sometimes called ‘zombie cells.’ They accumulate in aging tissue and cluster around tumors, where they create a protective environment that shields the cancer from immune attack. By targeting uPAR, the therapy strikes both the tumor and the senescent cell layer that surrounds and supports it.
One treatment, two targets
The dual mechanism is what makes this finding relevant beyond oncology. uPAR has been studied as a target for clearing senescent cells from aging tissue — not to treat cancer, but to slow aging itself. In that context, CAR T therapies are prohibitively expensive and complex for broad application. But in cancer treatment, these therapies are already deployed. The new research shows that uPAR-targeted CAR T cells penetrate deeper into solid tumors, remain active longer, and outperform previous approaches in animal models.
Clinical trials in humans are still at an early stage. And cost remains a formidable barrier — CAR T treatments routinely run to several hundred thousand dollars per patient — limiting who can access them regardless of efficacy. That’s not a scientific problem but a structural economic one, unlikely to be solved by better biology alone.
Aging and cancer are increasingly studied together
The study reflects a broader convergence in biomedical research: aging and cancer are being recognized as intertwined processes rather than separate fields. Senescent cells don’t just accumulate passively with age; they actively promote tumor growth by suppressing immune responses and secreting inflammatory signals. Therapies that address both simultaneously — the class of drugs called senolytics — are in active development across multiple research groups. Whether uPAR-targeted CAR T cells earn a place in that toolkit will depend on clinical trial results still years away.